[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
June 12, 2002

IND Submission Exemptions

Author Affiliations

Not Available

Not Available

JAMA. 2002;287(22):2936. doi:10.1001/jama.287.22.2936-JFD20006-2-1

The FDA has proposed a guidance for sponsors on what studies of marketed cancer drugs or biological products can be conducted without submitting an application for an investigational new drug (IND).

The proposal emphasizes that exemption from the IND requirement depends primarily on whether the investigation significantly increases risk associated with use of the product. Ordinarily, uses well above the recommended dose might be associated with increased risk. But because in oncology modifications of labeled dosing recommendations are common, oncology studies deviating from the approved labeling can be exempted, provided such changes are supported by the literature and generally known clinical experience.

First Page Preview View Large
First page PDF preview
First page PDF preview